Literature DB >> 18568033

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Dan Ehninger1, Sangyeul Han, Carrie Shilyansky, Yu Zhou, Weidong Li, David J Kwiatkowski, Vijaya Ramesh, Alcino J Silva.   

Abstract

Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568033      PMCID: PMC2664098          DOI: 10.1038/nm1788

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  29 in total

1.  CaMKIIalpha-Cre transgene expression and recombination patterns in the mouse brain.

Authors:  I Dragatsis; S Zeitlin
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  Developmental expression of the tuberous sclerosis proteins tuberin and hamartin.

Authors:  V Murthy; A O Stemmer-Rachamimov; L A Haddad; J E Roy; A N Cutone; R L Beauchamp; N Smith; D N Louis; V Ramesh
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

3.  Cognitive deficits in normally intelligent patients with tuberous sclerosis.

Authors:  J E Harrison; F J O'Callaghan; E Hancock; J P Osborne; P F Bolton
Journal:  Am J Med Genet       Date:  1999-12-15

4.  Neuroanatomical correlates of memory deficits in tuberous sclerosis complex.

Authors:  K Ridler; J Suckling; N J Higgins; P J de Vries; C M E Stephenson; P F Bolton; E T Bullmore
Journal:  Cereb Cortex       Date:  2006-04-07       Impact factor: 5.357

Review 5.  The growing role of mTOR in neuronal development and plasticity.

Authors:  Jacek Jaworski; Morgan Sheng
Journal:  Mol Neurobiol       Date:  2006-12       Impact factor: 5.590

6.  Biological markers of intellectual disability in tuberous sclerosis.

Authors:  Armin Raznahan; Nicholas P Higgins; Paul D Griffiths; Ayla Humphrey; John R W Yates; Patrick F Bolton
Journal:  Psychol Med       Date:  2007-03-05       Impact factor: 7.723

7.  The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus.

Authors:  Jessica L Banko; Francis Poulin; Lingfei Hou; Christine T DeMaria; Nahum Sonenberg; Eric Klann
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

8.  Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures.

Authors:  Susanna M I Goorden; Geeske M van Woerden; Louise van der Weerd; Jeremy P Cheadle; Ype Elgersma
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

Review 9.  Fragile X: translation in action.

Authors:  Mark F Bear; Gül Dölen; Emily Osterweil; Naveen Nagarajan
Journal:  Neuropsychopharmacology       Date:  2007-10-17       Impact factor: 7.853

Review 10.  The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment.

Authors:  Petrus J de Vries; Christopher J Howe
Journal:  Trends Mol Med       Date:  2007-07-13       Impact factor: 11.951

View more
  379 in total

1.  Social peers rescue autism-relevant sociability deficits in adolescent mice.

Authors:  Mu Yang; Kayla Perry; Michael D Weber; Adam M Katz; Jacqueline N Crawley
Journal:  Autism Res       Date:  2010-10-06       Impact factor: 5.216

2.  Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism.

Authors:  David M Young; A Katrin Schenk; Shi-Bing Yang; Yuh Nung Jan; Lily Yeh Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 3.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 4.  Local RNA translation at the synapse and in disease.

Authors:  Liqun Liu-Yesucevitz; Gary J Bassell; Aaron D Gitler; Anne C Hart; Eric Klann; Joel D Richter; Stephen T Warren; Benjamin Wolozin
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

5.  Dysregulation of mTOR signaling in neuropsychiatric disorders: therapeutic implications.

Authors:  Kirsty Sawicka; R Suzanne Zukin
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 6.  Translational control mechanisms in long-lasting synaptic plasticity and memory.

Authors:  Christos Gkogkas; Nahum Sonenberg; Mauro Costa-Mattioli
Journal:  J Biol Chem       Date:  2010-08-06       Impact factor: 5.157

Review 7.  Mechanisms of translational regulation in synaptic plasticity.

Authors:  Wayne S Sossin; Jean-Claude Lacaille
Journal:  Curr Opin Neurobiol       Date:  2010-04-27       Impact factor: 6.627

8.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

Review 9.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 10.  Activity-dependent neuronal signalling and autism spectrum disorder.

Authors:  Daniel H Ebert; Michael E Greenberg
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.